These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 38666539)

  • 1. Diagnostic Positron Emission Tomography Imaging with Zirconium-89 Desferrioxamine B Squaramide: From Bench to Bedside.
    Rudd SE; Noor A; Morgan KA; Donnelly PS
    Acc Chem Res; 2024 May; 57(9):1421-1433. PubMed ID: 38666539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging Somatostatin Positive Tumors with Tyr
    Noor A; Van Zuylekom JK; Rudd SE; Roselt PD; Haskali MB; Yan E; Wheatcroft M; Hicks RJ; Cullinane C; Donnelly PS
    Bioconjug Chem; 2021 Jul; 32(7):1192-1203. PubMed ID: 33788556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
    Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
    J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer.
    Noor A; Van Zuylekom JK; Rudd SE; Waldeck K; Roselt PD; Haskali MB; Wheatcroft MP; Yan E; Hicks RJ; Cullinane C; Donnelly PS
    J Med Chem; 2020 Sep; 63(17):9258-9270. PubMed ID: 32786229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Specifically Labeled
    Zheng M; Liu Q; Zhang H; Wang Y; Zhang K; Mu H; Fu F; Zhang X; Wang Y; Miao L
    Mol Pharm; 2024 Oct; 21(10):5205-5216. PubMed ID: 39322604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic versus Noncyclic Chelating Scaffold for
    Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
    Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light-Induced Radiosynthesis of
    Klingler S; Fay R; Holland JP
    J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
    Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
    Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.
    Zeglis BM; Lewis JS
    J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer.
    Parent EE; Gleba JJ; Knight JA; Kenderian SJ; Copland JA; Cai H
    Mol Imaging Biol; 2024 Oct; 26(5):847-857. PubMed ID: 39174789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-Specific
    Yue TTC; Ge Y; Aprile FA; Ma MT; Pham TT; Long NJ
    Bioconjug Chem; 2023 Oct; 34(10):1802-1810. PubMed ID: 37751398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.
    Salih AK; Raheem SJ; Garcia MD; Ahiahonu WK; Price EW
    Inorg Chem; 2022 Dec; 61(51):20964-20976. PubMed ID: 36516446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical
    Chomet M; Schreurs M; Bolijn MJ; Verlaan M; Beaino W; Brown K; Poot AJ; Windhorst AD; Gill H; Marik J; Williams S; Cowell J; Gasser G; Mindt TL; van Dongen GAMS; Vugts DJ
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):694-707. PubMed ID: 32889615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
    Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL
    J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabelling of the octadentate chelators DFO* and oxoDFO* with zirconium-89 and gallium-68.
    Brandt M; Cowell J; Aulsebrook ML; Gasser G; Mindt TL
    J Biol Inorg Chem; 2020 Aug; 25(5):789-796. PubMed ID: 32661784
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
    J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.